AbbVie Exceeds Quarterly Revenue and Profit Expectations as Newer Immunology Drugs Offset Humira Decline
AbbVie reported better-than-expected quarterly revenue and profit, driven by strong performance from newer immunology drugs Skyrizi and Rinvoq, which offset the declining sales of Humira. The company raised its full-year earnings forecast, signaling confidence in its transition away from Humira.
Tickers: $ABBV
Topics: Biosimilars Drug Sales Earnings Humira Portfolio Performance Profit Revenue Rinvoq Skyrizi